Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer

There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin ( CALR ) exon 9 mutations are driver mutations in patients with chronic myeloproliferat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Immunology, Immunotherapy Immunotherapy, 2020-02, Vol.69 (2), p.315-324
Hauptverfasser: Holmström, Morten Orebo, Cordua, Sabrina, Skov, Vibe, Kjær, Lasse, Pallisgaard, Niels, Ellervik, Christina, Hasselbalch, Hans Carl, Andersen, Mads Hald
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 324
container_issue 2
container_start_page 315
container_title Cancer Immunology, Immunotherapy
container_volume 69
creator Holmström, Morten Orebo
Cordua, Sabrina
Skov, Vibe
Kjær, Lasse
Pallisgaard, Niels
Ellervik, Christina
Hasselbalch, Hans Carl
Andersen, Mads Hald
description There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin ( CALR ) exon 9 mutations are driver mutations in patients with chronic myeloproliferative neoplasms (MPN), which are chronic blood cancers. The CALR mutations generate a neo-antigen that is recognized by patient T cells, and T cells isolated from a patient with a CALR -mutation can recognize and kill autologous CALR -mutant cells. Surprisingly, healthy individuals display frequent and strong T cell responses to the CALR neo-antigens too. Furthermore, healthy individuals display immune responses to all parts of the mutant CALR epitope, and the CALR neo-epitope specific responses are memory T cell responses. These data suggest that although healthy individuals might acquire a CALR mutation, the mutant cells can be eliminated by the immune system. Additionally, a small fraction of healthy individuals harbor a CALR exon 9 mutation. Four healthy individuals carrying CALR mutations underwent a full medical examination including a bone marrow biopsy after a median follow up of 6.2 years. None of these patients displayed any signs of CALR -mutant MPN. Additionally, all healthy individuals displayed strong CALR neo-epitope specific T cell responses suggesting that these healthy individuals retained their CALR -mutant cells in the editing stage for several years. Thus, we suggest that CALR -mutant MPN could be a disease model of cancer immuno-editing, as we have demonstrated that CALR -mutant MPN displays all three stages described in the theory of cancer immuno-editing.
doi_str_mv 10.1007/s00262-019-02473-y
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11027882</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2350714085</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-793964db8d311b2dac2b4339832832a6408889bcda31e7fb0e90d2a3abbe76fd3</originalsourceid><addsrcrecordid>eNp9kU9rGzEQxUVJaZy0XyCHIMi1247-rFc6hWDSJGDopT0LraS1FXYlR1o7-NtH7bpOcikIRsz85s2Dh9AFgW8EoPmeAeicVkBkBZQ3rNp_QDPCWWmJmpygGTAOVQPAT9FZzo_lQ0HKT-iUEUlqUfMZ6m533rpgHI4d9sOwDQ673g8-6NHH8HXqxcpZP_qwwjrYI5aN3jjsA94U1oUx42c_rvHaDXqMfVx5o3tsdBFPn9HHTvfZfTnUc_T7x-2vxX21_Hn3sLhZVoYzMlaNZHLObSssI6SlVhvacsakYLQ8PecghJCtsZoR13QtOAmWaqbb1jXzzrJzdD3pbrbt4KwprpLu1Sb5Qae9itqr95Pg12oVd4oQoI0QtChcHRRSfNq6PKrHuE2hmFaU1dCQ4qEuFJ0ok2LOyXXHEwTUn3DUFI4q4ai_4ah9Wbp8a-648i-NArAJyGUUVi693v6P7AtOfZ06</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2350714085</pqid></control><display><type>article</type><title>Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer</title><source>MEDLINE</source><source>SpringerNature Complete Journals</source><source>PubMed Central</source><creator>Holmström, Morten Orebo ; Cordua, Sabrina ; Skov, Vibe ; Kjær, Lasse ; Pallisgaard, Niels ; Ellervik, Christina ; Hasselbalch, Hans Carl ; Andersen, Mads Hald</creator><creatorcontrib>Holmström, Morten Orebo ; Cordua, Sabrina ; Skov, Vibe ; Kjær, Lasse ; Pallisgaard, Niels ; Ellervik, Christina ; Hasselbalch, Hans Carl ; Andersen, Mads Hald</creatorcontrib><description>There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin ( CALR ) exon 9 mutations are driver mutations in patients with chronic myeloproliferative neoplasms (MPN), which are chronic blood cancers. The CALR mutations generate a neo-antigen that is recognized by patient T cells, and T cells isolated from a patient with a CALR -mutation can recognize and kill autologous CALR -mutant cells. Surprisingly, healthy individuals display frequent and strong T cell responses to the CALR neo-antigens too. Furthermore, healthy individuals display immune responses to all parts of the mutant CALR epitope, and the CALR neo-epitope specific responses are memory T cell responses. These data suggest that although healthy individuals might acquire a CALR mutation, the mutant cells can be eliminated by the immune system. Additionally, a small fraction of healthy individuals harbor a CALR exon 9 mutation. Four healthy individuals carrying CALR mutations underwent a full medical examination including a bone marrow biopsy after a median follow up of 6.2 years. None of these patients displayed any signs of CALR -mutant MPN. Additionally, all healthy individuals displayed strong CALR neo-epitope specific T cell responses suggesting that these healthy individuals retained their CALR -mutant cells in the editing stage for several years. Thus, we suggest that CALR -mutant MPN could be a disease model of cancer immuno-editing, as we have demonstrated that CALR -mutant MPN displays all three stages described in the theory of cancer immuno-editing.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-019-02473-y</identifier><identifier>PMID: 31915854</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Animals ; Antigens ; Antigens, Neoplasm - immunology ; Autografts ; Biomarkers, Tumor ; Biopsy ; Blood cancer ; Bone marrow ; Calreticulin ; Calreticulin - genetics ; Calreticulin - metabolism ; Cancer ; Cancer Research ; Cell Transformation, Neoplastic ; Disease Models, Animal ; Disease Susceptibility ; Editing ; Epitopes ; Epitopes - immunology ; Focussed Research Review ; Hematologic Neoplasms - etiology ; Hematologic Neoplasms - metabolism ; Humans ; Immune evasion ; Immune system ; Immunological memory ; Immunology ; Immunomodulation - genetics ; Lymphocytes ; Lymphocytes T ; Medicine ; Medicine &amp; Public Health ; Memory cells ; Mutants ; Mutation ; Oncology ; Patients ; Tumor Escape - genetics</subject><ispartof>Cancer Immunology, Immunotherapy, 2020-02, Vol.69 (2), p.315-324</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><rights>Cancer Immunology, Immunotherapy is a copyright of Springer, (2020). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-793964db8d311b2dac2b4339832832a6408889bcda31e7fb0e90d2a3abbe76fd3</citedby><cites>FETCH-LOGICAL-c431t-793964db8d311b2dac2b4339832832a6408889bcda31e7fb0e90d2a3abbe76fd3</cites><orcidid>0000-0002-3764-8578</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11027882/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11027882/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,41467,42536,51297,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31915854$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Holmström, Morten Orebo</creatorcontrib><creatorcontrib>Cordua, Sabrina</creatorcontrib><creatorcontrib>Skov, Vibe</creatorcontrib><creatorcontrib>Kjær, Lasse</creatorcontrib><creatorcontrib>Pallisgaard, Niels</creatorcontrib><creatorcontrib>Ellervik, Christina</creatorcontrib><creatorcontrib>Hasselbalch, Hans Carl</creatorcontrib><creatorcontrib>Andersen, Mads Hald</creatorcontrib><title>Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><addtitle>Cancer Immunol Immunother</addtitle><description>There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin ( CALR ) exon 9 mutations are driver mutations in patients with chronic myeloproliferative neoplasms (MPN), which are chronic blood cancers. The CALR mutations generate a neo-antigen that is recognized by patient T cells, and T cells isolated from a patient with a CALR -mutation can recognize and kill autologous CALR -mutant cells. Surprisingly, healthy individuals display frequent and strong T cell responses to the CALR neo-antigens too. Furthermore, healthy individuals display immune responses to all parts of the mutant CALR epitope, and the CALR neo-epitope specific responses are memory T cell responses. These data suggest that although healthy individuals might acquire a CALR mutation, the mutant cells can be eliminated by the immune system. Additionally, a small fraction of healthy individuals harbor a CALR exon 9 mutation. Four healthy individuals carrying CALR mutations underwent a full medical examination including a bone marrow biopsy after a median follow up of 6.2 years. None of these patients displayed any signs of CALR -mutant MPN. Additionally, all healthy individuals displayed strong CALR neo-epitope specific T cell responses suggesting that these healthy individuals retained their CALR -mutant cells in the editing stage for several years. Thus, we suggest that CALR -mutant MPN could be a disease model of cancer immuno-editing, as we have demonstrated that CALR -mutant MPN displays all three stages described in the theory of cancer immuno-editing.</description><subject>Animals</subject><subject>Antigens</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Autografts</subject><subject>Biomarkers, Tumor</subject><subject>Biopsy</subject><subject>Blood cancer</subject><subject>Bone marrow</subject><subject>Calreticulin</subject><subject>Calreticulin - genetics</subject><subject>Calreticulin - metabolism</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Cell Transformation, Neoplastic</subject><subject>Disease Models, Animal</subject><subject>Disease Susceptibility</subject><subject>Editing</subject><subject>Epitopes</subject><subject>Epitopes - immunology</subject><subject>Focussed Research Review</subject><subject>Hematologic Neoplasms - etiology</subject><subject>Hematologic Neoplasms - metabolism</subject><subject>Humans</subject><subject>Immune evasion</subject><subject>Immune system</subject><subject>Immunological memory</subject><subject>Immunology</subject><subject>Immunomodulation - genetics</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Memory cells</subject><subject>Mutants</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Patients</subject><subject>Tumor Escape - genetics</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kU9rGzEQxUVJaZy0XyCHIMi1247-rFc6hWDSJGDopT0LraS1FXYlR1o7-NtH7bpOcikIRsz85s2Dh9AFgW8EoPmeAeicVkBkBZQ3rNp_QDPCWWmJmpygGTAOVQPAT9FZzo_lQ0HKT-iUEUlqUfMZ6m533rpgHI4d9sOwDQ673g8-6NHH8HXqxcpZP_qwwjrYI5aN3jjsA94U1oUx42c_rvHaDXqMfVx5o3tsdBFPn9HHTvfZfTnUc_T7x-2vxX21_Hn3sLhZVoYzMlaNZHLObSssI6SlVhvacsakYLQ8PecghJCtsZoR13QtOAmWaqbb1jXzzrJzdD3pbrbt4KwprpLu1Sb5Qae9itqr95Pg12oVd4oQoI0QtChcHRRSfNq6PKrHuE2hmFaU1dCQ4qEuFJ0ok2LOyXXHEwTUn3DUFI4q4ai_4ah9Wbp8a-648i-NArAJyGUUVi693v6P7AtOfZ06</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Holmström, Morten Orebo</creator><creator>Cordua, Sabrina</creator><creator>Skov, Vibe</creator><creator>Kjær, Lasse</creator><creator>Pallisgaard, Niels</creator><creator>Ellervik, Christina</creator><creator>Hasselbalch, Hans Carl</creator><creator>Andersen, Mads Hald</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3764-8578</orcidid></search><sort><creationdate>20200201</creationdate><title>Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer</title><author>Holmström, Morten Orebo ; Cordua, Sabrina ; Skov, Vibe ; Kjær, Lasse ; Pallisgaard, Niels ; Ellervik, Christina ; Hasselbalch, Hans Carl ; Andersen, Mads Hald</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-793964db8d311b2dac2b4339832832a6408889bcda31e7fb0e90d2a3abbe76fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Antigens</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Autografts</topic><topic>Biomarkers, Tumor</topic><topic>Biopsy</topic><topic>Blood cancer</topic><topic>Bone marrow</topic><topic>Calreticulin</topic><topic>Calreticulin - genetics</topic><topic>Calreticulin - metabolism</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Cell Transformation, Neoplastic</topic><topic>Disease Models, Animal</topic><topic>Disease Susceptibility</topic><topic>Editing</topic><topic>Epitopes</topic><topic>Epitopes - immunology</topic><topic>Focussed Research Review</topic><topic>Hematologic Neoplasms - etiology</topic><topic>Hematologic Neoplasms - metabolism</topic><topic>Humans</topic><topic>Immune evasion</topic><topic>Immune system</topic><topic>Immunological memory</topic><topic>Immunology</topic><topic>Immunomodulation - genetics</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Memory cells</topic><topic>Mutants</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Patients</topic><topic>Tumor Escape - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Holmström, Morten Orebo</creatorcontrib><creatorcontrib>Cordua, Sabrina</creatorcontrib><creatorcontrib>Skov, Vibe</creatorcontrib><creatorcontrib>Kjær, Lasse</creatorcontrib><creatorcontrib>Pallisgaard, Niels</creatorcontrib><creatorcontrib>Ellervik, Christina</creatorcontrib><creatorcontrib>Hasselbalch, Hans Carl</creatorcontrib><creatorcontrib>Andersen, Mads Hald</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Holmström, Morten Orebo</au><au>Cordua, Sabrina</au><au>Skov, Vibe</au><au>Kjær, Lasse</au><au>Pallisgaard, Niels</au><au>Ellervik, Christina</au><au>Hasselbalch, Hans Carl</au><au>Andersen, Mads Hald</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><stitle>Cancer Immunol Immunother</stitle><addtitle>Cancer Immunol Immunother</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>69</volume><issue>2</issue><spage>315</spage><epage>324</epage><pages>315-324</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><abstract>There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin ( CALR ) exon 9 mutations are driver mutations in patients with chronic myeloproliferative neoplasms (MPN), which are chronic blood cancers. The CALR mutations generate a neo-antigen that is recognized by patient T cells, and T cells isolated from a patient with a CALR -mutation can recognize and kill autologous CALR -mutant cells. Surprisingly, healthy individuals display frequent and strong T cell responses to the CALR neo-antigens too. Furthermore, healthy individuals display immune responses to all parts of the mutant CALR epitope, and the CALR neo-epitope specific responses are memory T cell responses. These data suggest that although healthy individuals might acquire a CALR mutation, the mutant cells can be eliminated by the immune system. Additionally, a small fraction of healthy individuals harbor a CALR exon 9 mutation. Four healthy individuals carrying CALR mutations underwent a full medical examination including a bone marrow biopsy after a median follow up of 6.2 years. None of these patients displayed any signs of CALR -mutant MPN. Additionally, all healthy individuals displayed strong CALR neo-epitope specific T cell responses suggesting that these healthy individuals retained their CALR -mutant cells in the editing stage for several years. Thus, we suggest that CALR -mutant MPN could be a disease model of cancer immuno-editing, as we have demonstrated that CALR -mutant MPN displays all three stages described in the theory of cancer immuno-editing.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>31915854</pmid><doi>10.1007/s00262-019-02473-y</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-3764-8578</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0340-7004
ispartof Cancer Immunology, Immunotherapy, 2020-02, Vol.69 (2), p.315-324
issn 0340-7004
1432-0851
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11027882
source MEDLINE; SpringerNature Complete Journals; PubMed Central
subjects Animals
Antigens
Antigens, Neoplasm - immunology
Autografts
Biomarkers, Tumor
Biopsy
Blood cancer
Bone marrow
Calreticulin
Calreticulin - genetics
Calreticulin - metabolism
Cancer
Cancer Research
Cell Transformation, Neoplastic
Disease Models, Animal
Disease Susceptibility
Editing
Epitopes
Epitopes - immunology
Focussed Research Review
Hematologic Neoplasms - etiology
Hematologic Neoplasms - metabolism
Humans
Immune evasion
Immune system
Immunological memory
Immunology
Immunomodulation - genetics
Lymphocytes
Lymphocytes T
Medicine
Medicine & Public Health
Memory cells
Mutants
Mutation
Oncology
Patients
Tumor Escape - genetics
title Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T22%3A04%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evidence%20of%20immune%20elimination,%20immuno-editing%20and%20immune%20escape%20in%20patients%20with%20hematological%20cancer&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=Holmstr%C3%B6m,%20Morten%20Orebo&rft.date=2020-02-01&rft.volume=69&rft.issue=2&rft.spage=315&rft.epage=324&rft.pages=315-324&rft.issn=0340-7004&rft.eissn=1432-0851&rft_id=info:doi/10.1007/s00262-019-02473-y&rft_dat=%3Cproquest_pubme%3E2350714085%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2350714085&rft_id=info:pmid/31915854&rfr_iscdi=true